Zuranolone and its role in treating major depressive disorder: a narrative review

References

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2019;393(10190):e44]. Lancet. 2018;392:1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7.Search in Google Scholar PubMed PubMed Central

2. Hecking, J, Davoudian, PA, Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders. Chronic Stress 2021;5. https://doi.org/10.1177/24705470211020446.Search in Google Scholar PubMed PubMed Central

3. Rahman, S, Alzarea, S. Glial mechanisms underlying major depressive disorder: potential therapeutic opportunities. Prog Mol Biol Transl Sci 2019;167:159–78. https://doi.org/10.1016/bs.pmbts.2019.06.010.Search in Google Scholar PubMed

4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013.10.1176/appi.books.9780890425596Search in Google Scholar

5. Hasin, DS, Sarvet, AL, Meyers, JL, Saha, TD, Ruan, WJ, Stohl, M, et al.. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatr 2018;75:336–46. https://doi.org/10.1001/jamapsychiatry.2017.4602.Search in Google Scholar PubMed PubMed Central

6. Kennedy, SH, Ceniti, AK. Unpacking major depressive disorder: from classification to treatment selection. Can J Psychiatry 2018;63:308–13. https://doi.org/10.1177/0706743717748883.Search in Google Scholar PubMed PubMed Central

7. Caspi, A, Sugden, K, Moffitt, TE, Taylor, A, Craig, IW, Harrington, H, et al.. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386–9. https://doi.org/10.1126/science.1083968.Search in Google Scholar PubMed

8. Kupferberg, A, Bicks, L, Hasler, G. Social functioning in major depressive disorder. Neurosci Biobehav Rev 2016;69:313–32. https://doi.org/10.1016/j.neubiorev.2016.07.002.Search in Google Scholar PubMed

9. Corfield, EC, Yang, Y, Martin, NG, Nyholt, DR. A continuum of genetic liability for minor and major depression. Transl Psychiatry 2017;7:e1131. https://doi.org/10.1038/tp.2017.99.Search in Google Scholar PubMed PubMed Central

10. Sullivan, PF, Neale, MC, Kendler, KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157:1552–62. https://doi.org/10.1176/appi.ajp.157.10.1552.Search in Google Scholar PubMed

11. Chiriţă, AL, Gheorman, V, Bondari, D, Rogoveanu, I. Current understanding of the neurobiology of major depressive disorder. Rom J Morphol Embryol 2015;56:651–8.Search in Google Scholar

12. American College of Physicians. ACP finds that cognitive behavioral therapy and second-generation antidepressants are similarly effective treatments for adults with major depressive disorder. American College of Physicians; 2021. https://www.acponline.org/acp-newsroom/acp-finds-that-cognitive-behavioral-therapy-and-second-generation-antidepressants-are-similarly [Accessed 24 Aug 2021].Search in Google Scholar

13. Qaseem, A, Snow, V, Denberg, TD, Forciea, MA, Owens, DK. Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians [published correction appears in Ann Intern Med. 2009 Jan 20;150(2):148]. Ann Intern Med 2008;149:725–33. https://doi.org/10.7326/0003-4819-149-10-200811180-00007.Search in Google Scholar PubMed

14. Gartlehner, G, Gaynes, BN, Hansen, RA, Thieda, P, DeVeaugh-Geiss, A, Krebs, EE, et al.. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008;149:734–50. https://doi.org/10.7326/0003-4819-149-10-200811180-00008.Search in Google Scholar PubMed

15. Qaseem, A, Barry, MJ, Kansagara, D. Clinical Guidelines Committee of the American College of Physicians. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;164:350–9. https://doi.org/10.7326/M15-2570.Search in Google Scholar PubMed

16. Arnaud, A, Suthoff, E, Stenson, K, Werneburg, B, Hodgkins, P, Bonthapally, V, et al.. Number needed to treat and number needed to harm analysis of the Zuranolone Phase II clinical trial results in major depressive disorder. J Affect Disord 2021;285:112–9. https://doi.org/10.1016/j.jad.2021.02.027.Search in Google Scholar PubMed

17. Althaus, AL, Ackley, MA, Belfort, GM, Gee, SM, Dai, J, Nguyen, DP, et al.. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator. Neuropharmacology 2020;181:108333. https://doi.org/10.1016/j.neuropharm.2020.108333.Search in Google Scholar PubMed PubMed Central

18. Hoffmann, E, Nomikos, GG, Kaul, I, Raines, S, Wald, J, Bullock, A, et al.. SAGE-217, A novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase I dose-finding studies. Clin Pharmacokinet 2020;59:111–20. https://doi.org/10.1007/s40262-019-00801-0.Search in Google Scholar PubMed PubMed Central

19. Möhler, H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res 2006;326:505–16. https://doi.org/10.1007/s00441-006-0284-3.Search in Google Scholar PubMed

20. Gunduz-Bruce, H, Silber, C, Kaul, I, Rothschild, AJ, Riesenberg, R, Sankoh, AJ, et al.. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 2019;381:903–11. https://doi.org/10.1056/NEJMoa1815981.Search in Google Scholar PubMed

21. Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62. https://doi.org/10.1136/jnnp.23.1.56.Search in Google Scholar PubMed PubMed Central

22. Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9. https://doi.org/10.1192/bjp.134.4.382.Search in Google Scholar PubMed

23. Busner, J, Targum, SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 2007;4:28–37.Search in Google Scholar

24. Hoddes, E, Zarcone, V, Smythe, H, Phillips, R, Dement, WC. Quantification of sleepiness: a new approach. Psychophysiology 1973;10:431–6. https://doi.org/10.1111/j.1469-8986.1973.tb00801.x.Search in Google Scholar PubMed

25. Posner, K, Brown, GK, Stanley, B, Brent, DA, Yershova, KV, Oquendo, MA, et al.. The columbia–suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatr 2011;168:1266–77. https://doi.org/10.1176/appi.ajp.2011.10111704.Search in Google Scholar PubMed PubMed Central

26. Sage, B. Therapeutics reports topline results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in major depressive disorder [Internet]. Cambridge: Businesswire; 2019. https://www.businesswire.com/news/home/20191205005375/en/Sage-TherapeuticsReports-Topline-Results-Pivotal-Phase [Accessed 26 Aug 2021].Search in Google Scholar

27. Clayton, A, Lasser, R, Nandy, I, Sankoh, AJ, Campbell, A, Werneburg, B, et al.. A phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult patients with major depressive disorder. Biol Psychiatr 2020;87:S86. https://doi.org/10.1016/J.BIOPSYCH.2020.02.242.Search in Google Scholar

28. National Institute of Health. A study to evaluate the efficacy of SAGE-217 in the treatment of adult subjects with major depressive disorder. NIH, U.S. National Library of Medicine; 2021. https://clinicaltrials.gov/ct2/show/NCT03672175 [Accessed 26 Aug 2021].Search in Google Scholar

29. Walkery, A, Leader, LD, Cooke, E, VandenBerg, A. Review of allopregnanolone agonist therapy for the treatment of depressive disorders. Drug Des Dev Ther 2021;15:3017–26. https://doi.org/10.2147/DDDT.S240856.Search in Google Scholar PubMed PubMed Central

30. National Institute of Health. A study to evaluate SAGE-217 in adult participants with Major Depressive Disorder (MDD). NIH, U.S. National Library of Medicine; 2021. https://clinicaltrials.gov/ct2/show/NCT03864614 [Accessed 27 Aug 2021].Search in Google Scholar

31. Cutler, A, Aaronson, ST, Mattingly, GW, Wilkinson, ST, Lasser, R, Nandy, I, et al.. Zuranolone in major depressive disorder: interim safety results from a phase 3, open-label, longitudinal study. Biol Psychiatr 2021;89:S161. https://doi.org/10.1016/J.BIOPSYCH.2021.02.413.Search in Google Scholar

32. Sage, B. Therapeutics announces positive interim, Topline Zuranolone Safety and Tolerability Data from open-label SHORELINE Study in patients with MDD [Internet]. Cambridge: Businesswire; 2020. https://www.businesswire.com/news/home/20201015005330/en/Sage-Therapeutics-Announces-Positive-Interim-Topline-Zuranolone-Safety-and-Tolerability-Data-from-Open-Label-SHORELINE-Study-in-Patients-with-MDD [Accessed 27 Aug 2021].Search in Google Scholar

33. National Institute of Health. A study to evaluate the efficacy of Sage-217 in the treatment of adult participants with Major Depressive Disorder (MDD). NIH, U.S. National Library of Medicine; 2021. https://clinicaltrials.gov/ct2/show/NCT04442490 [Accessed 27 Aug 2021].Search in Google Scholar

34. National Institute of Health. A comparative study of Sage-217 plus an Antidepressant (ADT) versus placebo plus an ADT in adults with major depressive disorder. NIH, U.S. National Library of Medicine; 2021. https://clinicaltrials.gov/ct2/show/NCT04476030 [Accessed 27 Aug 2021].Search in Google Scholar

35. Wilkinson, ST, Sanacora, G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today 2019;24:606–15. https://doi.org/10.1016/j.drudis.2018.11.007.Search in Google Scholar PubMed PubMed Central

36. Sanacora, G, Zarate, CA, Krystal, JH, Manji, HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426–37. https://doi.org/10.1038/nrd2462.Search in Google Scholar PubMed PubMed Central

37. FDA News Release. FDA approves first treatment for postpartum depression. Food and Drug Administration, United States of America; 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression [Accessed 27 Aug 2021].Search in Google Scholar

38. Ali, M, Aamir, A, Diwan, MN, Awan, HA, Ullah, I, Irfan, M, et al.. Treating postpartum depression: what do we know about brexanolone? Diseases 2021;9:52. https://doi.org/10.3390/diseases9030052.Search in Google Scholar PubMed PubMed Central

39. Psych Congress. Novel depression drug awarded FDA’s breakthrough therapy designation. Psych Congress Network; 2018. https://www.hmpgloballearningnetwork.com/site/pcn/article/novel-depression-drug-awarded-fdas-breakthrough-therapy-designation [Accessed 27 Aug 2021].Search in Google Scholar

40. Ogawa, Y, Takeshima, N, Hayasaka, Y, Tajika, A, Watanabe, N, Streiner, D, et al.. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev 2019;6:CD001026. https://doi.org/10.1002/14651858.CD001026.pub2.Search in Google Scholar PubMed PubMed Central

41. Rosenblat, JD. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 2019;381:2178–9. https://doi.org/10.1056/NEJMc1913170.Search in Google Scholar PubMed

42. Ten Doesschate, F, van Waarde, JA, van Wingen, GA. Non-superiority of zuranolone (SAGE-217) at the longer-term. J Affect Disord 2021;291:329–30. https://doi.org/10.1016/j.jad.2021.05.015.Search in Google Scholar PubMed

43. Deligiannidis, KM, Lasser, R, Gunduz-Bruce, H, Doherty, J, Jonas, J, Li, S, et al.. The ROBIN trial, a phase 3, double-blind, placebo-controlled trial of zuranolone in postpartum depression. In: Poster presented at: psych Congress 2020 Virtual Experience. Virtual 2020.Search in Google Scholar

44. Gunduz-Bruce, H, Lasser, R, Nandy, I, Sankoh, AJ, Jonas, J, Doherty, J, et al.. Open-label, Phase 2 trial of the oral neuroactive steroid GABAA receptor positive allosteric modulator zuranolone in bipolar disorder I and II. In: Poster presented at: psych Congress 2020 Virtual Experience. Virtual; 2020.Search in Google Scholar

45. World Health Organization. Depression – fact sheet. Geneva: World Health Organization; 2020. https://www.who.int/news-room/fact-sheets/detail/depression [Accessed 27 Aug 2021].Search in Google Scholar